BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10352875)

  • 1. IGIV in neurology--evidence and recommendations.
    Bril V; Allenby K; Midroni G; O'Connor PW; Vajsar J
    Can J Neurol Sci; 1999 May; 26(2):139-52. PubMed ID: 10352875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines on the use of intravenous immune globulin for neurologic conditions.
    Feasby T; Banwell B; Benstead T; Bril V; Brouwers M; Freedman M; Hahn A; Hume H; Freedman J; Pi D; Wadsworth L
    Transfus Med Rev; 2007 Apr; 21(2 Suppl 1):S57-107. PubMed ID: 17397768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
    Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute demyelinating motor neuropathy: an atypical form of the Guillain-Barre syndrome?].
    Corcia P; Beaume A; Guennoc AM; de Toffol B; Preud'homme JL; Autret A
    Rev Neurol (Paris); 1999 Sep; 155(8):596-7. PubMed ID: 10486851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Guillain-barre syndrome: immunoglobulins or plasmapheresis?].
    Martínez Yélamos A; Huerta Villanueva M; Olivé Plana M; Montero Homs J; Serra Catafau J; Martínez-Matos JA
    Neurologia; 1998 Apr; 13(4):166-9. PubMed ID: 9608755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?
    Elovaara I; Hietaharju A
    Acta Neurol Scand; 2010 Nov; 122(5):309-15. PubMed ID: 20085560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Patwa HS; Chaudhry V; Katzberg H; Rae-Grant AD; So YT
    Neurology; 2012 Mar; 78(13):1009-15. PubMed ID: 22454268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 May; 41(5):812-23. PubMed ID: 17440006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues.
    Gold R; Stangel M; Dalakas MC
    Nat Clin Pract Neurol; 2007 Jan; 3(1):36-44. PubMed ID: 17205073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.
    Donofrio PD; Berger A; Brannagan TH; Bromberg MB; Howard JF; Latov N; Quick A; Tandan R
    Muscle Nerve; 2009 Nov; 40(5):890-900. PubMed ID: 19768755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
    Dalakas MC
    Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
    Bascić-Kes V; Kes P; Zavoreo I; Lisak M; Zadro L; Corić L; Demarin V;
    Acta Clin Croat; 2012 Dec; 51(4):673-83. PubMed ID: 23540178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin therapy for neurological disorders.
    Harkins C; Hammond-Tooke G; Faed J
    N Z Med J; 2009 Oct; 122(1305):41-6. PubMed ID: 19966877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous IgG for treatment of neuromuscular diseases].
    Vedeler CA; Mellgren SI; Omdal R; Torbergsen T; Aasly J
    Tidsskr Nor Laegeforen; 2010 Sep; 130(17):1717-20. PubMed ID: 20835282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients.
    Busby M; Donaghy M
    J Neurol; 2003 Jun; 250(6):714-24. PubMed ID: 12796835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of intravenous immunoglobulin in neurological disorders].
    Steck AJ
    Rev Med Suisse; 2005 Apr; 1(17):1167-70. PubMed ID: 15941089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous immunoglobulins in neurology].
    Vuillemet F; Tranchant C; Warter JM
    Presse Med; 1993 Nov; 22(34):1741-4. PubMed ID: 8302781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.
    Elovaara I; Apostolski S; van Doorn P; Gilhus NE; Hietaharju A; Honkaniemi J; van Schaik IN; Scolding N; Soelberg Sørensen P; Udd B;
    Eur J Neurol; 2008 Sep; 15(9):893-908. PubMed ID: 18796075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of intravenous immunglobulin in the treatment of autoimmune neuromuscular diseases].
    Molnár MJ
    Ideggyogy Sz; 2006 Mar; 59(3-4):98-106. PubMed ID: 16634454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study.
    Merkies IS; Bril V; Dalakas MC; Deng C; Donofrio P; Hanna K; Hartung HP; Hughes RA; Latov N; van Doorn PA;
    Neurology; 2009 Apr; 72(15):1337-44. PubMed ID: 19365055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.